Available Technologies by Category
T cell Secretion of Engineered Enzymatic Weapons for Solid Tumor Translation
  • This innovation involves genetically modifying human cells to secrete an enzyme that breaks down adenosine, enhancing CAR-T and other T cell therapies' effectiveness against solid tumors.
  • The prototype addresses adenosine-mediated immunosuppression, improving therapy specificity and efficacy in treating solid tumors.
  • It has commercial applications in enhancing CAR-T cell therapies and other immunotherapy treatments for various cancers, marking a significant advancement in cancer care.
8854
An Electronic Microfluidic Platform for On-Chip Apoptosis Quantification using Annexin V-Based PS Externalization Detection-GT NEXT
  • This electronic microchip integrates an electrical sensor network with a microfluidic capture chamber to detect phosphatidylserine (PS) externalization, offering a compact, user-friendly, and cost-effective solution for apoptotic analysis.
  • The prototype provides high sensitivity and specificity without the need for prelabeling, making it suitable for diverse applications in clinical diagnostics and biomedical research.
  • It supports drug discovery, toxicity evaluation, and bioprocessing optimizations, enhancing disease mechanism studies and therapeutic target identification.
9306
Antigen-specific Cell Programming Using non-viral Approaches
  • This innovative technology uses synthetic nanoparticles to deliver gene modulators and engineered MHC molecules directly to antigen-specific T cells in vivo, enhancing T cell functions and bypassing ex vivo processes.
  • The prototype improves T cell specificity and reduces off-target toxicity, significantly lowering costs and manufacturing time for effective T cell therapies.
  • It has applications in cancer therapy, immune therapy, autoimmune disease therapy, and infectious disease therapy.
8703
Scarless isolation of antigen-specific T cells for CAR T cell manufacturing via DNA-gated sorting
  • This technology introduces DNA-gated sorting (DGS) for label-free isolation of antigen-specific CD8+ T cells, improving CAR T cell therapy.
  • The prototype enhances CAR T cell scalability and therapeutic effectiveness against solid tumors by using a DNA gate mechanism for targeted T cell capture and release.
  • DGS improves in vivo persistence and specificity of CAR T cells, offering better treatment outcomes for solid tumors and other cancers.
9388
Activity-based synthetic liquid biopsy of solid tumors
  • Activatable biosensors injected into tumors capture dynamic biological activity and immune responses, allowing non-invasive monitoring of tumor responses through bodily fluids.
  • The prototype offers real-time insights into tumor behavior and treatment effectiveness, providing a less invasive alternative to traditional biopsies.
  • This method enhances sensitivity and specificity for tumor-specific biomarkers, improving monitoring of drug responses and cancer progression.
9387
Needle-like Nanostructures to Deliver Multi-scale Biomolecules to Non-activated Immune Cells
  • This functionalized nanowire platform delivers multiple genetic materials to naïve T and B cells without pre-activation, enhancing their efficacy in adoptive cell therapy.
  • The prototype improves gene delivery efficiency while preserving the naïve state of immune cells, increasing cell viability and immune response modulation.
  • It offers superior protection against intracellular pathogens and serves as a research tool for immune cell manipulation across various species, ages, and subtypes.
9341
Multi-Niche Human Bone Marrow-On-A-Chip for Plasma Cell Survival and Differentiation
  • This novel microfluidic chip simulates the human bone marrow environment, incorporating multiple niches and supporting long-term plasma cell culture and study.
  • The prototype enables comprehensive study of plasma cell maturation, aiding the development of targeted therapies for plasma cell-related disorders.
  • It overcomes limitations in traditional plasma cell culture, facilitating vaccine development, antibody production research, and immune response modulation.
9246
Lymphoid-Lymphatics-Integrated Organ-on-Chip Device and Method
  • This innovative organ-on-chip system combines vascularized lung and lymphoid tissues, aiding studies on airway infections.
  • The prototype supports diverse cell cultures, making it useful for screening treatments and vaccines.
  • It enhances current lung-on-chip models by accurately simulating lung tissue and immune responses.
9349
Functionalized Nanowires for miRNA-mediated Programming of Naive T Cells
  • Technology Overview: Georgia Tech's functionalized nanowires deliver genetic materials like miRNAs and CRISPR directly to naive T cells, enhancing their therapeutic potential without pre-activation.
  • Advantages: This method preserves the naive state of T cells, allowing for better viability and functionality, reduced exhaustion, and delivery of both small and large biomolecules, including lentiviral particles.
  • Commercial Applications: The technology can be used in adoptive T cell therapy for cancer and infectious diseases, therapeutic delivery of biomolecules, and as a research tool for immune cell manipulation.
9341
Lymphoid Tissues with Switchable Protein Gradients
  • Technology Overview: Georgia Tech's hydrogel-based immune organoids mimic lymphoid tissue, enabling ex vivo differentiation of B cells and studying immune responses to infections and vaccinations.
  • Advantages: This non-invasive method supports long-term B and T cell survival, mimics antibody production processes, and offers insights into diseases like lymphoma.
  • Commercial Applications: Useful for drug discovery, clinical research on immune disorders, personalized medicine, and academic studies in immunology.
2024-116
Engineering Antigen-Specific T Cells for CAR T Cell Therapy via Antigen-Presenting Lipid Nanoparticles
  • Technology Overview: Georgia Tech's new CAR T cell therapy uses lipid nanoparticles (LNPs) to program antigen-specific T cells in vivo, potentially reducing costs and production time.

  • Advantages: This approach avoids expensive and time-consuming ex vivo manufacturing, minimizes off-target effects, can adapt to various CAR constructs and cancer types, and promises rapid scaling and reduced costs.

  • Commercial Applications: Applicable to multiple myeloma, CD19+ cancers, and a wide range of other cancers, this technology streamlines CAR T cell therapy manufacturing for faster, more affordable treatments.

9386
Driving Neural Activity to Rapidly Control Inflammation, Protein, and Gene Expression in the Brain
  • Novel non-invasive method utilizing neural activity to swiftly control inflammation, protein, and gene expression in the brain.
  • The technology enables rapid and precise modulation of brain functions, potentially revolutionizing treatment for various neurological conditions.
  • Commercial applications include treating Alzheimer's, schizophrenia, autism, epilepsy, and more, offering faster, non-invasive, and targeted therapeutic options.
7773
Lipid Nanoparticle-Mediated Delivery of mRNA Encoded Synthetic Antigens for CAR T Cell Therapy
  • Georgia Tech's novel CAR T cell therapy uses lipid nanoparticles (LNPs) to deliver mRNA-encoded synthetic antigens, improving targeting of solid tumors and reducing off-target effects.

  • The technology ensures efficient mRNA delivery, prompting tumor cells to express unique antigens, enhancing immune recognition and destruction of cancer cells.

  • This approach broadens CAR T cell therapy applicability, allows repeat dosing, and minimizes off-tumor toxicity, offering significant advantages over traditional methods.

9385
Acousto-Optical Sensors for MRI Safety Evaluation
  • The invention is an acousto-optical sensor that can measure the SAR (specific absorption rate) in its environment through temperature and the radio frequency (RF) field.
  • The innovation can be used to improve patient safety during MRI scans and to ensure MRI-compatibility for medical implants.
  • The solution is more compact and flexible than market alternatives
7953
Novel Hydrogels for Encapsulation, Vascularization, and Transplantation of Cells
  • This hydrolytically degradable poly(ethylene glycol) (PEG) hydrogel leverages ester linkages combined at various ratios with non-degradable macromers to enable tunable degradation kinetics.
  • Potential applications include controlled release and delivery of drugs or proteins as well as cell encapsulation. It can also be used as a delivery vehicle and adhesive for cells in transplantation settings.
  • These innovative hydrogels allow for rapid hydrolytic cleavage in vivo but remain stable in vitro for weeks at neural pH 7 to support regenerative medicine techniques.
9019
Low-Cost, Efficient Intracellular Delivery of Proteins and Nucleic Acids via Hydrophobic Ion Pairing
  • Safe and efficient approach of delivering therapeutics to disease by mixing cargo and charged hydrophobic ions with cells.
  • Applications in therapeutic/drug delivery, protein transduction reagent, and gene transduction reagent.
  • Enables efficacious delivery of a wide range of protein and nucleic acid therapeutics.
9178
Scalable Manufacturing Approach of Graded Polymer Thin Film Has Potential for Widespread Use
  • Combines slot die coating with a custom roll-to-roll imaging system to allow for efficient, rapid, and scalable fabrication of high-quality gradient thin films.
  • An improved manufacturing process over existing techniques because it uses broad material combinations and yields higher quality patterned thin films.
  • Incorporates multiple materials to increase the application of patterned thin films across industries, including microelectronics, energy technologies, and environmental systems.
8994
Improving Quantitative Phase Imaging to Enhance Reliability and Broaden Applications
  • Universal application of an OBM/qOBM optical phase imaging device is made possible by the optimized SNR that identifies configurations with fewer limitations (e.g., conditions, tissue).
  • The simulated SNR can identify non-intuitive geometries for optical phase imaging devices that previously may not have been identified by the arduous experimental optimization process. 
  • Optimized SNR when OBM/qOBM devices take in-vivo and in-situ measurements have been proven reliable across multiple types of tissue.
8936
Messenger RNA–Based Expression of Cardiomyocyte Phenotype Sensors and Differentiating Genes for In Vitro Correction of Cardiac Disorders
  • This invention uses a gene therapy as a direct treatment for symptomatic bradyarrhythmia and removes the needs for implantation of electronic pacemakers.
  • The innovation does not lead to spillover to the liver, spleen and lungs; allows for mRNA gene transfer to stay focal to the injection site; and does not have danger of integration into the host’s DNA.
  • The new gene therapy could be used as first-line treatment of arrhythmias and consequent ailments and to circumvent the need for major surgical interventions.
7526
Smart Nanosensor-Embedded Stent System for Wireless Surveillance of Restenosis in Coronary Artery Disease
  • An electronic stent that incorporates an ultrathin stretchable wireless sensor for continuous surveillance of restenosis along with neointimal proliferation and plaque deposition.
  • There is no existing system that offers a clinically practical solution for continuous, real- time detection of both restenosis incidence and progression.
  • This device will profoundly decrease the number of healthcare dollars spent on repeated revascularization due to restenosis in CAD.
8542